Target family: Dopamine receptors (type: gpcr)
Target: D<sub>3</sub> receptor

Ligand: perospirone (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: yes
Median affinity: 9.550000190734863 pKi
Reference (Journal): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Published in: Eur J Pharmacol

Ligand: PF-592379 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.670000076293945 pIC50
Reference (Journal): Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats.
Published in: Behav Pharmacol

Ligand: PG01037 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.2 pKi
Reference (Journal): Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.
Published in: J Med Chem

Ligand: pimozide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Median affinity: 7.4 pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: pimozide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Median affinity:  pKi
Reference (Journal): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Published in: Eur J Pharmacol

Ligand: pimozide (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1984)
Median affinity:  pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: piribedil (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity: 6.6 pKi
Reference (Journal): Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: pramipexole (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA and EMA (1997)
Primary target: yes
Median affinity:  pKi
Reference (Journal): A functional test identifies dopamine agonists selective for D<sub>3</sub>versus D<sub>2</sub>receptors.
Published in: Neuroreport

Ligand: pramipexole (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA and EMA (1997)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Published in: Eur J Pharmacol

Ligand: prochlorperazine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1956)
Primary target: yes
Median affinity: 8.350000381469727 pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: promazine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1956)
Primary target: yes
Median affinity: 6.800000190734863 pKi
Reference (Journal): Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
Published in: J Pharmacol Exp Ther

Ligand: quinelorane (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
Published in: J Pharmacol Exp Ther

Ligand: quinelorane (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Published in: Eur J Pharmacol

Ligand: quinpirole (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Published in: Eur J Pharmacol

Ligand: quinpirole (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
Published in: J Pharmacol Exp Ther

Ligand: quinpirole (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: quinpirole (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.
Published in: Nature

Ligand: quinpirole (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: quinpirole (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Published in: Eur J Pharmacol

Ligand: quinpirole (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): A functional test identifies dopamine agonists selective for D<sub>3</sub>versus D<sub>2</sub>receptors.
Published in: Neuroreport